{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:26:11Z","timestamp":1761895571567},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2012,10,1]]},"DOI":"10.2174\/187152012803529727","type":"journal-article","created":{"date-parts":[[2012,10,29]],"date-time":"2012-10-29T19:23:29Z","timestamp":1351538609000},"page":"1098-1109","source":"Crossref","is-referenced-by-count":18,"title":["JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?"],"prefix":"10.2174","volume":"12","author":[{"given":"Fabio","family":"P. S. Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/103583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T14:35:39Z","timestamp":1448289339000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/openurl\/content.php?genre=article&issn=1871-5206&volume=12&issue=9&spage=1098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,1]]},"references-count":0,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,10,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/187152012803529727","relation":{},"ISSN":["1871-5206"],"issn-type":[{"value":"1871-5206","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10,1]]}}}